Generic Name Brand Name Manufacturer Indication(s) Route of Administration Month Approved* aprocitentan Tryvio® Idosia Difficult-to-control or resistant hypertension Oral March budesonide Eohilia™...

The 2026 Medical Pharmacy Trend Report: Part 1– Payer Survey reflects Prime Therapeutics’ long standing commitment to delivering trusted, data driven perspectives that shape the industry...

Industry experts share new insights from PBM industry, including GLP-1 weight-loss drugs, biosimilars and rising pharmaceutical costs

Prime Therapeutics’ Clinical Insights is your trusted resource for timely, evidence based perspectives on emerging therapies and managed care strategy. The Summer 2025 issue focuses on metabolic...

Prime Therapeutics clinical experts shared insights on the specialty drug pipeline at recent industry event

Real-world data reveal a persistent challenge: helping patients maintain GLP-1 treatment long enough to realize its full benefits

Lassen, chief clinical officer at Prime Therapeutics/Magellan Rx, shares insights on GLP-1 weight-loss drugs and evidence-based approaches to providing the kind of care we’d want for our loved ones.

Generic Name Brand Name Brand Manufacturer Indication Approval Month* chikungunya vaccine, live Ixchiq® Valneva Austria Prevention of disease caused by Chikungunya virus November meningococcal...